Flexion Therapeutics (FLXN) Earning Somewhat Positive Press Coverage, Study Finds

News coverage about Flexion Therapeutics (NASDAQ:FLXN) has been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Flexion Therapeutics earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned news coverage about the specialty pharmaceutical company an impact score of 45.5821188018192 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Here are some of the media stories that may have effected Accern Sentiment’s rankings:

Flexion Therapeutics (FLXN) opened at $25.66 on Monday. Flexion Therapeutics has a one year low of $16.17 and a one year high of $32.25. The company has a current ratio of 12.93, a quick ratio of 12.93 and a debt-to-equity ratio of 0.87.

FLXN has been the subject of a number of analyst reports. BMO Capital Markets restated a “buy” rating on shares of Flexion Therapeutics in a research report on Friday, August 11th. Needham & Company LLC restated a “buy” rating and issued a $36.00 price target (up previously from $34.00) on shares of Flexion Therapeutics in a research report on Thursday, August 10th. Wells Fargo & Company set a $39.00 price target on Flexion Therapeutics and gave the stock a “buy” rating in a research report on Friday, October 6th. Northland Securities reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Flexion Therapeutics in a research note on Wednesday, October 4th. Finally, Royal Bank Of Canada set a $44.00 price objective on Flexion Therapeutics and gave the stock a “buy” rating in a research note on Monday, September 11th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $98.33.

In related news, insider Neil Bodick acquired 2,700 shares of the stock in a transaction dated Tuesday, November 21st. The stock was acquired at an average cost of $24.49 per share, with a total value of $66,123.00. Following the purchase, the insider now directly owns 64,605 shares of the company’s stock, valued at $1,582,176.45. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Michael D. Clayman acquired 5,000 shares of the stock in a transaction dated Wednesday, November 8th. The stock was bought at an average cost of $23.60 per share, with a total value of $118,000.00. Following the completion of the purchase, the insider now directly owns 35,395 shares in the company, valued at $835,322. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 8,700 shares of company stock valued at $208,323. 15.98% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: “Flexion Therapeutics (FLXN) Earning Somewhat Positive Press Coverage, Study Finds” was originally published by Week Herald and is owned by of Week Herald. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://weekherald.com/2017/12/04/flexion-therapeutics-flxn-getting-somewhat-favorable-news-coverage-report-shows.html.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Insider Buying and Selling by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply